Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.36 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987683 | 0.94 | TRPC3 (0.40) | RXFP1MAPTLMNATP53USP30 | |
| SCHEMBL22987919 | 0.93 | MAPT (0.39) | RXFP1MAPTLMNATP53USP30 | |
| SCHEMBL22987628 | 0.93 | MAPT (0.39) | RXFP1MAPTLMNATP53USP30 | |
| SCHEMBL22987465 | 0.93 | TP53 (0.39) | RXFP1MAPTLMNATP53USP30 | |
| SCHEMBL22988052 | 0.92 | MAPT (0.42) | RXFP1MAPTLMNATP53USP30 | |
| SCHEMBL25118867 | 0.90 | ADORA3 (0.40) | MAPTTP53TRPC3TRPC7PARP1 | |
| SCHEMBL22988171 | 0.90 | ADORA3 (0.35) | RXFP1USP30TRPC3TRPC7KMT2A | |
| SCHEMBL22988001 | 0.88 | NR1H2 (0.33) | RXFP1MAPTTP53USP30TRPC3 | |
| SCHEMBL22988270 | 0.88 | USP30 (0.34) | RXFP1USP30TRPC3TRPC7KMT2A | |
| SCHEMBL30393069 | 0.88 | USP30 (0.34) | RXFP1USP30TRPC3TRPC7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | RXFP1 154/4885MAPT 4047/4885LMNA 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.